Company intelligence / Profile preview

Beijing Sanwater Biological Technology Co., Ltd.

Ownership: Private
Development stage: Phase 1

Overview

Beijing Sanwater Biological Technology is conducting a Phase 1 clinical trial (NCT02810223) to determine the efficacy and safety of CART-19 cell therapy in patients with chemo-refractory and relapsed B-cell acute lymphoblastic leukemia. The trial is a single arm, open-label, multi-center study that began on May 1, 2016.[1][7]

Therapeutic areas: Oncology
Modalities: CAR-T cell therapy
Industry: Biotech

Drug pipeline

1 asset

CD19 CAR-T

Phase 1

Indications: B-cell acute lymphoblastic leukemia

Beyond the preview

Go deeper on Beijing Sanwater Biological Technology Co., Ltd..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Beijing Sanwater Biological Technology Co., Ltd..

Explore the full profile